de Barclays Bio-Rad Laboratories Class A BIO Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | USD 78.6 M | Vender |
267,634
-11,201
| -4% | -USD 3.18 M | 0.02% | 579 |
|
|
2026
Q1 | USD 77.7 M | Comprar |
278,835
+254,341
| +1,038% | +USD 73.2 M | 0.02% | 580 |
|
|
2025
Q4 | USD 7.42 M | Vender |
24,494
-8,172
| -25% | -USD 2.55 M | ﹤0.01% | 1914 |
|
|
2025
Q3 | USD 9.16 M | Comprar |
32,666
+12,818
| +65% | +USD 3.49 M | ﹤0.01% | 1728 |
|
|
2025
Q2 | USD 4.79 M | Vender |
19,848
-10,001
| -34% | -USD 2.36 M | ﹤0.01% | 2172 |
|
|
2025
Q1 | USD 7.27 M | Vender |
29,849
-10,570
| -26% | -USD 3.18 M | ﹤0.01% | 1632 |
|
|
2024
Q4 | USD 13.3 M | Vender |
40,419
-1,557
| -4% | -USD 528 k | ﹤0.01% | 1363 |
|
|
2024
Q3 | USD 14 M | Vender |
41,976
-5,406
| -11% | -USD 1.72 M | ﹤0.01% | 1253 |
|
|
2024
Q2 | USD 12.9 M | Comprar |
47,382
+7,528
| +19% | +USD 2.19 M | ﹤0.01% | 1088 |
|
|
2024
Q1 | USD 13.8 M | Vender |
39,854
-22,098
| -36% | -USD 7.27 M | ﹤0.01% | 1194 |
|
|
2023
Q4 | USD 20 M | Comprar |
61,952
+16,747
| +37% | +USD 5.25 M | 0.01% | 1049 |
|
|
2023
Q3 | USD 16.2 M | Comprar |
45,205
+1,245
| +3% | +USD 480 k | 0.01% | 823 |
|
|
2023
Q2 | USD 16.7 M | Comprar |
43,960
+20,554
| +88% | +USD 8.36 M | 0.01% | 789 |
|
|
2023
Q1 | USD 11.2 M | Vender |
23,406
-42,996
| -65% | -USD 20.1 M | 0.01% | 1111 |
|
|
2022
Q4 | USD 27.9 M | Comprar |
66,402
+12,293
| +23% | +USD 4.96 M | 0.01% | 730 |
|
|
2022
Q3 | USD 22.6 M | Comprar |
54,109
+30,863
| +133% | +USD 15.4 M | 0.02% | 563 |
|
|
2022
Q2 | USD 11.5 M | Vender |
23,246
-4,628
| -17% | -USD 2.41 M | 0.01% | 956 |
|
|
2022
Q1 | USD 15.7 M | Vender |
27,874
-8,911
| -24% | -USD 5.37 M | 0.01% | 765 |
|
|
2021
Q4 | USD 27.8 M | Vender |
36,785
-8,878
| -19% | -USD 6.64 M | 0.01% | 809 |
|
|
2021
Q3 | USD 34.1 M | Comprar |
45,663
+12,847
| +39% | +USD 9.6 M | 0.02% | 676 |
|
|
2021
Q2 | USD 21.1 M | Comprar |
32,816
+509
| +2% | +USD 310 k | 0.01% | 873 |
|
|
2021
Q1 | USD 18.5 M | Comprar |
32,307
+11,397
| +55% | +USD 6.75 M | 0.01% | 830 |
|
|
2020
Q4 | USD 12.2 M | Vender |
20,910
-40
| -0.2% | -USD 22.8 k | 0.01% | 1076 |
|
|
2020
Q3 | USD 10.8 M | Comprar |
20,950
+419
| +2% | +USD 212 k | 0.01% | 1003 |
|
|
2020
Q2 | USD 9.27 M | Vender |
20,531
-6,354
| -24% | -USD 2.8 M | 0.01% | 1010 |
|
|
2020
Q1 | USD 9.42 M | Comprar |
26,885
+353
| +1% | +USD 130 k | 0.01% | 1020 |
|
|
2019
Q4 | USD 9.8 M | Vender |
26,532
-8,193
| -24% | -USD 2.89 M | 0.01% | 1417 |
|
|
2019
Q3 | USD 11.6 M | Comprar |
34,725
+3,528
| +11% | +USD 1.15 M | 0.01% | 1197 |
|
|
2019
Q2 | USD 9.8 M | Comprar |
31,197
+26,508
| +565% | +USD 7.94 M | 0.01% | 1370 |
|
|
2019
Q1 | USD 1.43 M | Vender |
4,689
-42,017
| -90% | -USD 11.3 M | ﹤0.01% | 2993 |
|
|
2018
Q4 | USD 10.8 M | Comprar |
46,706
+39,653
| +562% | +USD 10.6 M | 0.01% | 1105 |
|
|
2018
Q3 | USD 2.21 M | Comprar |
7,053
+2,784
| +65% | +USD 864 k | ﹤0.01% | 2760 |
|
|
2018
Q2 | USD 1.23 M | Vender |
4,269
-1,216
| -22% | -USD 336 k | ﹤0.01% | 3058 |
|
|
2018
Q1 | USD 1.37 M | Vender |
5,485
-2,052
| -27% | -USD 522 k | ﹤0.01% | 2849 |
|
|
2017
Q4 | USD 1.8 M | Comprar |
7,537
+6,157
| +446% | +USD 1.49 M | ﹤0.01% | 2535 |
|
|
2017
Q3 | USD 307 k | Vender |
1,380
-2,917
| -68% | -USD 656 k | ﹤0.01% | 4051 |
|
|
2017
Q2 | USD 972 k | Comprar |
4,297
+56
| +1% | +USD 12.2 k | ﹤0.01% | 2918 |
|
|
2017
Q1 | USD 846 k | Comprar |
4,241
+3,321
| +361% | +USD 640 k | ﹤0.01% | 2879 |
|
|
2016
Q4 | USD 168 k | Comprar |
920
+370
| +67% | +USD 63.1 k | ﹤0.01% | 4351 |
|
|
2016
Q3 | USD 91 k | Vender |
550
-502
| -48% | -USD 76.2 k | ﹤0.01% | 4569 |
|
|
2016
Q2 | USD 149 k | Comprar |
1,052
+384
| +57% | +USD 54.8 k | ﹤0.01% | 4133 |
|
|
2016
Q1 | USD 91 k | Comprar |
668
+54
| +9% | +USD 7.09 k | ﹤0.01% | 4410 |
|
|
2015
Q4 | USD 85 k | Comprar |
614
+39
| +7% | +USD 5.41 k | ﹤0.01% | 4502 |
|
|
2015
Q3 | USD 77 k | Vender |
575
-108
| -16% | -USD 15.5 k | ﹤0.01% | 4779 |
|
|
2015
Q2 | USD 103 k | Vender |
683
-3,396
| -83% | -USD 486 k | ﹤0.01% | 4646 |
|
|
2015
Q1 | USD 551 k | Comprar |
4,079
+446
| +12% | +USD 55.3 k | ﹤0.01% | 3537 |
|
|
2014
Q4 | USD 435 k | Vender |
3,633
-933
| -20% | -USD 107 k | ﹤0.01% | 4001 |
|
|
2014
Q3 | USD 516 k | Vender |
4,566
-1,181
| -21% | -USD 140 k | ﹤0.01% | 3921 |
|
|
2014
Q2 | USD 684 k | Vender |
5,747
-4,906
| -46% | -USD 599 k | ﹤0.01% | 3685 |
|
|
2014
Q1 | USD 1.36 M | Comprar |
10,653
+2,025
| +23% | +USD 260 k | ﹤0.01% | 2917 |
|
|
2013
Q4 | USD 1.06 M | Comprar |
8,628
+3,956
| +85% | +USD 482 k | ﹤0.01% | 3332 |
|
|
2013
Q3 | USD 547 k | Comprar |
4,672
+1,725
| +59% | +USD 203 k | ﹤0.01% | 4014 |
|
|
2013
Q2 | USD 330 k | Comprar |
+2,947
| Nuevas | +USD 346 k | ﹤0.01% | 4695 |
|
Otros fondos que tienen BIO en su cartera
Posición de Barclays en BIO: resumen de T2 2026
Barclays redujo su participación en Bio-Rad Laboratories Class A (BIO) en 4% durante T2 2026, al vender acciones por un valor estimado de USD 3.18 M, y conservó 267,634 acciones valuadas en USD 78.6 M. La posición representa 0.02% de la cartera y ocupa el puesto #579.
Barclays reportó por primera vez una posición en BIO en T2 2013 y la ha mantenido durante 53 trimestres desde entonces. Al cierre de T2 2026, 401 fondos que sigue Wall St. Rank mantienen una posición en BIO.
- Al cierre de T2 2026, Barclays tenía 267,634 acciones de Bio-Rad Laboratories Class A con un valor de USD 78.6 M.
- Barclays vendió 11,201 acciones de Bio-Rad Laboratories Class A en T2 2026, por un valor estimado de USD 3.18 M.
- Bio-Rad Laboratories Class A representó 0.02% de la cartera de Barclays en T2 2026 y fue su posición número 579.
- Barclays reportó por primera vez una posición en Bio-Rad Laboratories Class A en T2 2013 y la ha mantenido durante 53 trimestres desde entonces.
- Al cierre de T2 2026, 401 fondos que sigue Wall St. Rank tenían Bio-Rad Laboratories Class A en cartera.
Según el Informe 13F de Barclays correspondiente a T2 2026, presentado el 14 ago 2026.